Physician profile
Vinay Singh
NPI 1558590513
$479.65
in general payments reported to CMS, 2019-2025
12 companies · $18.38 in 2025
The $18.38 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $27.57 · 2021: $62.09 · 2022: $151 · 2023: $48.48 · 2024: $172 · 2025: $18.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $238.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $130.92 | 2022 | |
| Novo Nordisk INC | $72.69 | 2021-2024 | Ozempic, Rybelsus |
| Abbott Laboratories | $39.32 | 2022-2024 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $36.76 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $36.38 | 2024 | Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.27 | 2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $31.01 | 2024 | |
| Janssen Pharmaceuticals, INC | $28.42 | 2020-2021 | |
| Pfizer INC. | $25.94 | 2020-2021 | |
| Dexcom, INC. | $17.64 | 2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $14.58 | 2024 | Minimed 780g |
| E.R. Squibb & Sons, L.L.C. | $13.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinay Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.